<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01489306</url>
  </required_header>
  <id_info>
    <org_study_id>MDT-637-CP-102</org_study_id>
    <nct_id>NCT01489306</nct_id>
  </id_info>
  <brief_title>A Trial to Assess the Safety, Tolerability and Pharmacokinetics of MDT-637 in Healthy Volunteers</brief_title>
  <official_title>A Randomized, Double-blind, Placebo-controlled Study to Assess the Safety, Tolerability and Pharmacokinetics of Inhaled MDT-637 Administered to Healthy Volunteers for 10 Days</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>MicroDose Therapeutx, Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>MicroDose Therapeutx, Inc</source>
  <brief_summary>
    <textblock>
      The purpose of the study is to assess the tolerability and safety of a range of repeated
      inhaled doses of MDT-637. This includes monitoring effects on pulmonary function and
      determination of blood levels of MDT-637 following inhalation.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2011</start_date>
  <completion_date type="Actual">February 2012</completion_date>
  <primary_completion_date type="Actual">February 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and Tolerability of 3 escalating doses of MDT-637 dry powder inhalation in healthy volunteers</measure>
    <time_frame>Up to 48 days (including up to 28 days of screening period)</time_frame>
    <description>Safety measurements include Clinical Laboratory Evaluations, Pulmonary Function Tests (Spirometry), ECG, Vital Signs, Physical Examination and Assessment of Adverse Events.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Plasma pharmacokinetics for MDT-637 dry powder inhalation</measure>
    <time_frame>Multiple plasma samples collected during the dosing period, upto 24 hr post last dose</time_frame>
    <description>Plasma Samples will be measured to determine MDT-637 pharmacokinetics</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">36</enrollment>
  <condition>Drug Safety</condition>
  <arm_group>
    <arm_group_label>MDT-637</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Active formulation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matched Placebo Comparator</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MDT-637</intervention_name>
    <description>Inhaled doses of MDT-637 over a 10 day period</description>
    <arm_group_label>MDT-637</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MDT-637</intervention_name>
    <description>Inhaled doses of MDT-637 over a 10 day period</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Males and/or surgically sterile or post-menopausal females (confirmed by FSH test);
             males must agree to practice barrier contraception until they are discharged from the
             study

          -  Willing to give written informed consent

          -  18 to 50 years of age

          -  BMI of 19-30 kg/m2

          -  Non-smoker (for at least 90 days prior to screening) and willing to abstain from
             smoking during the course of the study

          -  Good general health as determined by medical history, physical examination,
             spirometry, ECG and clinical laboratory tests

          -  Willing to abstain from alcohol, caffeine, and xanthine-containing beverages for 24
             hours prior to and 24 hours after dosing

        Exclusion Criteria:

          -  Uncontrolled, clinically significant disease which in the opinion of the Principal
             Investigator and Sponsor (MDTx) would place the subject at risk through study
             participation or would confound the assessment of the safety of MDT-637

          -  Evidence of current or history of respiratory disease; for instance asthma, emphysema,
             chronic bronchitis or cystic fibrosis.

          -  Upper respiratory tract infection within 6 weeks of Visit 1

          -  Symptoms of rhinitis (stuffy nose, rhinorrhea, sneezing, nasal discharge) within 2
             weeks of Visit 1

          -  Current symptoms of cough, dyspnea, wheezing or nocturnal awakenings due to
             respiratory symptoms

          -  History of significant nasal irritation from nasal inhalation of medication

          -  History of malignancy

          -  History of clinically significant alcohol or drug abuse

          -  Positive drug screen for drugs of abuse

          -  Positive test for HIV, Hepatitis B or Hepatitis C

          -  Allergy to lactose, or lactose intolerance

          -  Use of prescription medication within 14 days of Visit 2 or over-the-counter
             preparations, including dietary and herbal supplements, within 5 days of Visit 2

          -  Positive urine pregnancy test at Visit 1

          -  Inability to perform reproducible spirometry in accordance with American Thoracic
             Society/European Respiratory Society (ATS/ERS) guidelines

          -  Abnormal QTc interval at Visit 1(&gt;450 msec in males or &gt; 470 msec in females)

          -  Significant blood donation (or testing) in previous 8 weeks
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>West Coast Clinical Trials</name>
      <address>
        <city>Cypress</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 7, 2011</study_first_submitted>
  <study_first_submitted_qc>December 8, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 9, 2011</study_first_posted>
  <last_update_submitted>April 10, 2012</last_update_submitted>
  <last_update_submitted_qc>April 10, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 12, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Respiratory Syncytial Virus Infection</keyword>
  <keyword>RSV</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

